Clinical trial · Interventional
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)
Pilot Study to Assess the Safety and Effectiveness of the Use of BioTraceIO 360 for PSM and Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures
NCT05641922CI-TRIAL-00071702PANORAMA2withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Withdrawn by Sponsor
Summary
Brief summary (as posted)
Pilot study planned to demonstrate the safety and effectiveness of the use of BioTraceIO 360 for Planning, Monitoring and Assessment of liver tissue ablation procedures Single-center prospective single-arm clinical investigation. Sample size - 10 subjects.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Metastatic Liver Cancer | Malignant Liver Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BioTraceIO 360 | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BioTrace
- description
- Use of the BioTraceIO 360 device for planning, monitoring and assessment of liver tissue ablations
- interventionNames
- Device: BioTraceIO 360
Primary outcomes (2)
- measure
- Effectiveness
- timeFrame
- 1 year
- description
- The percentage of patients for whom (1) probe(s) position suggestion provided by the BioTraceIO 360 device is in agreement with the planned probe(s) position, as determined by the physician without the use of the device, or (2) clinically feasible probe(s) positioning suggestion was provided by the BioTraceIO 360 device, in addition to the planned probe(s) position by the physician without the use of the device
- measure
- Safety
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Scheduled and indicated for standard-of-care liver tumor ablation for either hepatocellular carcinoma (HCC) or metastatic liver tumor(s) microwave (MW) energy. * Patient must have at least one prior CT or CECT scan (up to 6 months before enrollment). * Tumor must be visualized on at least one diagnostic imaging modality (MRI or contrast-enhanced CT). * Single tumor, or multiple tumors only if the distance between the ablated tumor and all other tumors allows for distinct separation between the necrotic zones. * Distance between the tumor and the edge of any previous necrotic zones allows for distinct separation between the necrotic zones. * At least 21 years of age. * Able and willing to give informed consent. Additional inclusion criteria for subgroup: \- Single ablation, using a single ablation needle, per tumor. Exclusion Criteria: * Planned ablation includes adjunctive means other than MW energy (e.g., ethanol, hepatic artery embolization, etc.). * Planned ablation includes the use of more than two ablation needles, per tumor * Ablation area cannot be visualized and monitored continuously using ultrasound throughout the entire ablation procedure. * Pregnant or breastfeeding. * Patient judged unsuitable for study participation by the physician for any other reason. * Currently participating in another clinical trial of an unapproved investigational device or drug that has not concluded the follow-up period. * Unable or unwilling to give informed consent. Additional exclusion criteria for subgroup: * Liver tumor that cannot be ablated with a single ablation needle, according to the investigator's clinical opinion. * Planned ablation includes repositioning and/or overlapping ablations using a single ablation needle.
References
Publications (0)
Data not yet available
No reference posted for this study.